50-1-211. (Temporary) Task force on cervical cancer. (1) There is a task force on cervical cancer established in the department of public health and human services.
     (2) The task force must be composed of at least 7 and no more than 10 members and must include:
     (a) an obstetrician-gynecologist;
     (b) a registered nurse;
     (c) a physician in family practice;
     (d) a member from the cancer research community;
     (e) a state epidemiologist;
     (f) a cervical cancer survivor; and
     (g) a pediatrician.
     (3) The task force members must be appointed by the director to 2-year terms. The task force shall meet quarterly as needed. The task force members may be reimbursed for expenses as provided in 2-18-501 through 2-18-503. Additional members may be added to the task force upon a majority vote of the members.
     (4) The task force shall:
     (a) review statistical and qualitative data on the use and effectiveness of the human papillomavirus vaccine;
     (b) identify strategies for educating the public regarding the availability and efficacy of human papillomavirus vaccine, including appropriate methods for informing and educating parents and adolescents about the risks of human papillomavirus disease, modes of transmission, and availability of a vaccine;
     (c) identify and examine the limitations of existing laws, regulations, programs, and services with regard to immunizations;
     (d) consider the medical, social, financial, and ethical implications of requiring human papillomavirus vaccination of adolescents for continued enrollment in school;
     (e) facilitate coordination of and communication between state and local agencies and organizations;
     (f) receive and consider reports and testimony from individuals, including cervical cancer survivors, from leaders on the issue of cervical cancer, and from local health departments, community-based organizations, and voluntary health organizations.
     (5) The task force shall issue a report to the children, families, health, and human services interim committee by August 1, 2008:
     (a) detailing its findings regarding the use and efficacy of the human papillomavirus vaccine in adolescents;
     (b) recommending strategies or actions regarding vaccination of adolescents; and
     (c) recommending strategies or actions for the education of the public regarding human papillomavirus disease, modes of transmission, and availability of a vaccine. (Terminates June 30, 2009--sec. 2, Ch. 473, L. 2007.)

     History: En. Sec. 1, Ch. 404, L. 2005; amd. Sec. 1, Ch. 473, L. 2007.